
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics Inc. possesses a positive outlook as its product candidate, lorundrostat, has demonstrated a significant, robust, and differentiated benefit in patients with uncontrolled and resistant hypertension, showing a placebo-adjusted blood pressure reduction exceeding 10 mmHg. The clinical advantage of lorundrostat, as highlighted in discussions with key opinion leaders (KOLs), positions the drug favorably compared to Phase 3 competitors, thereby enhancing its market potential in a critical therapeutic area. Furthermore, the company's focus on near-term FDA feedback and an anticipated New Drug Application (NDA) submission indicates strong progress toward commercialization, which bodes well for future financial performance.
Bears say
Mineralys Therapeutics Inc faces significant risks that negatively impact its financial outlook, including the potential failure of its product candidate lorundrostat to meet peak commercial revenue estimates due to limitations in market size, penetration rates, and pricing strategies. Additionally, the company may struggle to secure adequate capital resources necessary to support ongoing operations and the development of its programs, which presents a further challenge to its financial stability. Lastly, concerns regarding patient safety, particularly related to potassium levels and potential hyperkalemia, could impede the product's commercialization and acceptance in the market.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares